Ruxolitinib Cream is Associated With Reduced Treatment Burden in Atopic Dermatitis: A US Payer Claim Analysis

Main Article Content

Karen Miller
Citrus Health Group

Jinan Liu
Incyte Corporation

Bonnie H. Bui
Optum

Nnaemeka U. Odo
Optum

Tim Bancroft
Optum

Daniel Sturm
Incyte Corporation

Keywords

Topical therapy, Biologic therapy

References

1. Guttman-Yassky E, et al. Lancet. 2025;405(10478):P583-P596.

2. Sidbury R, et al. J Am Acad Dermatol. 2023;89(1):e1-e20.

3. Quintás-Cardama A, et al. Blood. 2010;115(15):3109-3117.

4. Eichenfield LF, et al. J Am Acad Dermatol. 2025;93(3):689-698.

5. Eichenfield LF, et al. 52-week safety and disease control with ruxolitinib cream in children aged 2–11 years with atopic dermatitis: results from the phase 3 TRuE-AD3 study. Presented at: 33rd European Academy of Dermatology and Venereology (EADV) Congress; September 25-28, 2024; Amsterdam, The Netherlands.

6. Papp K, et al. J Am Acad Dermatol. 2023;88(5):1008-1016.

7. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

8. Opzelura® (ruxolitinib cream). Full Prescribing Information. Incyte Corporation; 2025.

9. Liu J, et al. Association of ruxolitinib cream initiation with continued reduction in use of other topical treatments, oral corticosteroids, and biologics for atopic dermatitis. Presented at: Fall Clinical Dermatology Conference; October 24-27, 2024; Las Vegas, NV, USA.

10. Liu J, et al. Clinicoecon Outcomes Res. 2025;17:69-77.

11. Hu W, et al. Am J Clin Dermatol. 2024;25(2):327-332.

12. Liu J, et al. Ruxolitinib cream utilization reduced other topical therapy, corticosteroid, and biologic use in patients with atopic dermatitis: US claims database analysis. Presented at: Academy of Managed Care Pharmacy Nexus; October 14-17, 2024; Las Vegas, NV, USA.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/9yfem502

Article Details

How to Cite
1.
Ruxolitinib Cream is Associated With Reduced Treatment Burden in Atopic Dermatitis: A US Payer Claim Analysis. J of Skin. 2025;9(6):s591. doi:10.25251/9yfem502
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Poster Presentations from FC25 Dermatology Conference®: Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)